Peptide Monographs

BPC-157

BPC-157 is a peptide, indexed here under Tissue repair peptides.

Identity

Measured identity values, each with the source that reports it
FieldValue
ClassificationPeptide
Primary classTissue repair peptides
CAS registry number137525-51-0[1]
PubChem CID9941957[1]
UniProt accessionUnknown No UniProt query was run in v1.
Molecular formulaC62H98N16O22[1]
Molecular weight1419.5 g/mol[1]
Amino-acid sequenceUnknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1.
Reported half-lifeUnknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated.

What the cited literature examines

BPC-157 is a pentadecapeptide. Its retrieved literature is almost entirely preclinical and originates from a small number of research groups. The earliest retrieved report, in Life Sciences in 1994, concerns gastric and duodenal lesions; a 1997 European Journal of Pharmacology paper examines its influence on stomach mucosa integrity and blood pressure in relation to nitric oxide synthase inhibition.

Musculoskeletal endpoints appear in a 2011 Journal of Applied Physiology report on tendon healing involving tendon outgrowth, cell survival and cell migration, and in a 2014 Molecules paper on growth hormone receptor expression in tendon fibroblasts. A 2014 Current Pharmaceutical Design paper frames the compound in terms of a relation to the nitric oxide system. A 2007 European Journal of Pharmacology paper reports on the PL 14736 designation in wound healing.

[3, 4, 5, 6, 7, 8]

Reported mechanism

The retrieved literature frames the mechanism in terms of a relation to the nitric oxide system, and reports effects on growth hormone receptor expression in tendon fibroblasts. No single receptor target is established in the retrieved record set.

[7, 6]

Stated in the titles of the cited 2014 Current Pharmaceutical Design and 2014 Molecules papers.

Targets named in the cited records: nitric oxide system, growth hormone receptor.

FDA application register

A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]

Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.

Retrieved 2026-10-09.

Amounts reported in the cited literature

Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.

No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.

Adverse effects reported in the cited literature

Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.

No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.

Other names

BPC-157 appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.

Where this page sits

Research records

Cited research records for BPC-157, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.

Side-by-side pages that include BPC-157

Compounds indexed next to it

Named targets in the cited records

Class page: Tissue repair peptides. Full index: all indexed compounds.

Questions this page answers

What does the cited literature examine for BPC-157?

BPC-157 is a pentadecapeptide. Its retrieved literature is almost entirely preclinical and originates from a small number of research groups.

Which class is BPC-157 indexed under?

BPC-157 is indexed under Tissue repair peptides. This grouping covers peptides whose retrieved research literature is predominantly concerned with tissue repair endpoints in laboratory and animal models, rather than a single shared receptor.

What does the FDA application register show for BPC-157?

A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.

Sources

  1. PubChem Compound Summary for CID 9941957, Bpc-157. PubChem, National Library of Medicine (2026). pubchem:9941957
  2. Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:bpc-157
  3. The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides. Life Sci (1994). pmid:7904712
  4. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. Eur J Pharmacol (1997). pmid:9298922
  5. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985) (2011). pmid:21030672
  6. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules (2014). pmid:25415472
  7. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des (2014). pmid:23755725
  8. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Eur J Pharmacol (2007). pmid:17628536

On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.

Further reading